Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets

11 Jul 2019

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc. Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Related Aurobindo Pharma Ltd. Links:

Aurobindo Pharma Share Price

796.55 -5.05 (-0.63%) Sep 29, 18:01
1 Year Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 505.60
Dr. Reddys Lab 5083.50
Lupin 998.00
Piramal Enterprises 1253.15
Cadila Healthcare 387.55
View more..
Sensex vs Aurobindo Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback